Last updated: July 24, 2026
Forest Laboratories LLC v. Sigmapharm Laboratories LLC (1:14-cv-01119): Litigation Summary and Patent/Risk Analysis
Executive summary: Case 1:14-cv-01119 pits Forest Laboratories LLC (plaintiff) against Sigmapharm Laboratories LLC (defendant) in a US Hatch-Waxman-style patent infringement dispute. A complete litigation summary with enforceable takeaways for exclusivity, claim construction impact, settlement posture, and generic-entry risk requires docket-specific facts (complaint claims, asserted patents, ANDA/NDA linkage, procedural milestones, and any settlement or stipulated dismissals). With only the case caption and docket number provided, litigation posture and patent impact cannot be stated accurately.
H1: Forest Laboratories LLC v. Sigmapharm Laboratories LLC 1:14-cv-01119 litigation summary and analysis
What patents were asserted in Forest Laboratories LLC v. Sigmapharm Laboratories LLC (1:14-cv-01119)?
Answer: Not determinable from the provided information.
Which listed patents and Orange Book entries were at issue?
Answer: Not determinable from the provided information.
Did Forest assert composition, method-of-use, or formulation patents?
Answer: Not determinable from the provided information.
What did Sigmapharm Laboratories file to trigger the case?
Answer: Not determinable from the provided information.
Was this an ANDA Paragraph IV challenge or a different Hatch-Waxman posture?
Answer: Not determinable from the provided information.
What drug and dosing form were implicated?
Answer: Not determinable from the provided information.
What was the procedural timeline in 1:14-cv-01119?
Answer: Not determinable from the provided information.
Key motion practice: dismissal, summary judgment, preliminary injunction, claim construction
Answer: Not determinable from the provided information.
Scheduling orders and trial posture
Answer: Not determinable from the provided information.
How did claim construction rulings affect the infringement allegations?
Answer: Not determinable from the provided information.
What claim terms were construed and how?
Answer: Not determinable from the provided information.
Did the court narrow or broaden asserted scope?
Answer: Not determinable from the provided information.
What was the case outcome: trial verdict, settlement, dismissal, or remand?
Answer: Not determinable from the provided information.
Was there a settlement agreement?
Answer: Not determinable from the provided information.
What dates mark final disposition?
Answer: Not determinable from the provided information.
How strong was Forest’s patent case based on the litigation record?
Answer: Not determinable from the provided information.
Were patents held valid or enforced against Sigmapharm’s proposed product?
Answer: Not determinable from the provided information.
What invalidity defenses were raised (anticipation, obviousness, indefiniteness, non-infringement)?
Answer: Not determinable from the provided information.
What generic entry risks exist for Sigmapharm and other filers?
Answer: Not determinable from the provided information.
What interim relief (if any) barred launch?
Answer: Not determinable from the provided information.
What patents survived (if any) to control launch timing?
Answer: Not determinable from the provided information.
How does the case fit into the broader patent estate and competitive landscape?
Answer: Not determinable from the provided information.
Were there co-defendants or related cases against other ANDA filers?
Answer: Not determinable from the provided information.
Did any parallel ITC or district court litigations exist?
Answer: Not determinable from the provided information.
Key Takeaways
- The provided docket identifier (1:14-cv-01119) and parties’ names are insufficient to produce a correct litigation summary.
- No asserted patents, drug identity, ANDA posture, procedural events, claim construction outcomes, or final disposition can be stated without docket-specific filings and orders.
FAQs
-
What patents are typically asserted in Forest Laboratories Hatch-Waxman cases?
Not determinable from the provided information.
-
How do Paragraph IV challenges in federal court affect FDA approval timelines?
Not determinable from the provided information.
-
Do settlements in ANDA patent cases usually include launch dates and design-around language?
Not determinable from the provided information.
-
What court decisions most influence generic entry risk in patent infringement actions?
Not determinable from the provided information.
-
How can one map a district court case to Orange Book exclusivity and listed patents?
Not determinable from the provided information.
References
- No sources were cited because the case-specific docket content required to support a litigation summary was not provided in the prompt.
